The Absorption, Clearance and Metabolic Fate of Dermatan Sulphate Administered to Man - Studies Using a Radioiodinated Derivative

Summary

An iodinated derivative of dermatan sulphate was administered by the intravenous, subcutaneous and oral routes to healthy human volunteers in conjunction with unlabelled dermatan sulphate. Following intravenous injection clearance of radiolabel and concentration as measured by competitive binding assay were highly correlated and displayed complex kinetics which were not dose-dependent. Intact ¹²⁵I-dermatan sulphate was absorbed following both subcutaneous and oral administration, though there appeared to be selective uptake by the gut of a subfraction comprising the smaller or less sulphated molecules. The intact material was subsequently excreted unchanged in the urine. Degradation products of dermatan sulphate were not detected by either gel filtration or affinity chromatography on Polybrene-Sepharose at any time in either plasma or urine, indicating that administered dermatan sulphate is not catabolised by man.

Keywords

Dermatan sulphate - Iodinated derivative - Pharmacokinetics - Absorption - Catabolism

• References

• 1 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 2 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA. Heparin sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-747
• 3 Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 4 Sié P, Fernandez F, Caranobe C, Gabaig AM, Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate. Thromb Res 1982; 35: 231-236
• 5 Fernandez F, van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317
• 6 Dawes J, Hodson BA, MacGregor IR, Pepper DS, Prowse CV. Pharmacokinetic and biological activities of dermatan sulfate (Mediolanum MF701) in healthy human volunteers. Ann N Y Acad Sci 1989; 556: 292-303
• 7 Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, Sie P, Boneu B. Pharmacodynamics and pharmacokinetics of dermatan sulfate in man. Blood. 1989. (in press)
• 8 Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
• 9 MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulphate in man - catabolism of iodinated derivatives. Thromb Haemostas 1984; 51: 321-325
• 10 Dol F, Houin G, Dupouy D, Cadroy Y, Caranobe C, Gabaig AM, Mardiguian J, Sie P, Boneu B. Pharmacokinetics of dermatan sulfate in the rabbit after intravenous injection. Thromb Haemostas 1988; 59: 255-258
• 11 Greenwood FC, Hunter WM, Glover JS. The preparation of ¹³¹I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-123
• 12 Irimura T, Nakajima M, di Ferrante N, Nicolson GL. High-speed gel permeation chromatography of glycosaminoglycans; its application to the analysis of heparan sulphate of embryonic carcinoma and its degradation products by tumor cell-derived heparanase. Anal Biochem 1983; 130: 461-468
• 13 Dawes J. Measurement of the affinities of heparins, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin. Anal Biochem 1988; 174: 177-186
• 14 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
• 15 Dawes J, Prowse CV, Pepper DS. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemostas 1985; 54: 630-634